Nu Med Grupa S.A.

The medical center is at the forefront of Non-Small Cell Lung Cancer research, focusing on innovative therapies for early-stage and advanced cases. The center's work includes evaluating the efficacy of durvalumab and osimertinib in combination with radiation therapy, aiming to improve progression-free survival (PFS) in patients with specific genetic mutations.

• Durvalumab with SBRT for T1 to T3N0M0 NSCLC
• Osimertinib post-SBRT for EGFR mutation-positive NSCLC
• Durvalumab with chemoradiation for unresectable Stage III NSCLC

These studies contribute to personalized treatment approaches, enhancing outcomes for patients with unresected Stage I/II and locally advanced NSCLC.

In the realm of Hepatocellular Carcinoma, the center is pioneering treatments for non-resectable cases. The MONTBLANC study explores the sequential or up-front use of durvalumab, tremelimumab, and bevacizumab, comparing their efficacy against historical controls.

• Sequential triple therapy for HCC
• Up-front triple therapy for HCC

This research aims to establish new standards in the management of advanced liver cancer, offering hope for improved survival rates.

The center is committed to advancing oncology treatments through ongoing studies that provide continuous care for patients who benefit from previous trials. This includes those with locally advanced and metastatic NSCLC, as well as urothelial carcinoma and small-cell lung cancer.

• Durvalumab for Stage III NSCLC
• Post-chemotherapy urothelial carcinoma
• First-line treatment for Stage IV SCLC

By monitoring safety and tolerability, the center ensures that patients continue to receive effective therapies, contributing to the broader field of cancer treatment.